FLNA logo

Filana Therapeutics, Inc. Stock Price

NasdaqCM:FLNA Community·US$94.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author

FLNA Share Price Performance

US$1.99
-0.80 (-28.67%)
US$1.99
-0.80 (-28.67%)
Price US$1.99

FLNA Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with moderate risk.

5 Risks
0 Rewards

Filana Therapeutics, Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$91.0m

Other Expenses

-US$91.0m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-1.88
0%
0%
0%
View Full Analysis

About FLNA

Founded
1998
Employees
30
CEO
Richard Barry
WebsiteView website
www.filanatx.com

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Recent FLNA News & Updates

Recent updates

No updates